Advertisement
NVAX or REPL or SRRK
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NVAX’s FA Score shows that 1 FA rating(s) are green whileREPL’s FA Score has 1 green FA rating(s), and SRRK’s FA Score reflects 0 green FA rating(s).
- NVAX’s FA Score: 1 green, 4 red.
- REPL’s FA Score: 1 green, 4 red.
- SRRK’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NVAX’s TA Score shows that 6 TA indicator(s) are bullish while REPL’s TA Score has 5 bullish TA indicator(s), and SRRK’s TA Score reflects 4 bullish TA indicator(s).
- NVAX’s TA Score: 6 bullish, 4 bearish.
- REPL’s TA Score: 5 bullish, 4 bearish.
- SRRK’s TA Score: 4 bullish, 6 bearish.
Price Growth
NVAX (@Biotechnology) experienced а +14.46% price change this week, while REPL (@Biotechnology) price change was +1.46% , and SRRK (@Biotechnology) price fluctuated -1.71% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +9.90%. For the same industry, the average monthly price growth was +26.70%, and the average quarterly price growth was +20.91%.
Reported Earning Dates
NVAX is expected to report earnings on Nov 05, 2025.
REPL is expected to report earnings on Nov 18, 2025.
SRRK is expected to report earnings on Nov 17, 2025.
Industries' Descriptions
@Biotechnology (+9.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| NVAX | REPL | SRRK | |
| Capitalization | 1.56B | 434M | 3.02B |
| EBITDA | 555M | -235.43M | -268.99M |
| Gain YTD | 19.154 | -54.088 | -27.325 |
| P/E Ratio | 4.32 | N/A | N/A |
| Revenue | 1.22B | 0 | 0 |
| Total Cash | 731M | 484M | 364M |
| Total Debt | 229M | 76.2M | 63.1M |
NVAX | REPL | SRRK | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 21 | 84 | 52 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 84 Overvalued | 18 Undervalued | 67 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 76 | |
SMR RATING 1..100 | 100 | 97 | 98 | |
PRICE GROWTH RATING 1..100 | 40 | 97 | 40 | |
P/E GROWTH RATING 1..100 | 10 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 50 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REPL's Valuation (18) in the Biotechnology industry is somewhat better than the same rating for SRRK (67) and is significantly better than the same rating for NVAX (84). This means that REPL's stock grew somewhat faster than SRRK’s and significantly faster than NVAX’s over the last 12 months.
SRRK's Profit vs Risk Rating (76) in the Biotechnology industry is in the same range as REPL (100) and is in the same range as NVAX (100). This means that SRRK's stock grew similarly to REPL’s and similarly to NVAX’s over the last 12 months.
REPL's SMR Rating (97) in the Biotechnology industry is in the same range as SRRK (98) and is in the same range as NVAX (100). This means that REPL's stock grew similarly to SRRK’s and similarly to NVAX’s over the last 12 months.
SRRK's Price Growth Rating (40) in the Biotechnology industry is in the same range as NVAX (40) and is somewhat better than the same rating for REPL (97). This means that SRRK's stock grew similarly to NVAX’s and somewhat faster than REPL’s over the last 12 months.
NVAX's P/E Growth Rating (10) in the Biotechnology industry is significantly better than the same rating for SRRK (100) and is significantly better than the same rating for REPL (100). This means that NVAX's stock grew significantly faster than SRRK’s and significantly faster than REPL’s over the last 12 months.
| NVAX | REPL | SRRK | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 74% | 2 days ago 87% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 75% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 87% | 2 days ago 80% | 2 days ago 88% |
| MACD ODDS (%) | 2 days ago 88% | 2 days ago 81% | 2 days ago 84% |
| TrendWeek ODDS (%) | 2 days ago 83% | 2 days ago 81% | 2 days ago 87% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 86% | 2 days ago 89% |
| Advances ODDS (%) | 2 days ago 84% | 2 days ago 78% | N/A |
| Declines ODDS (%) | 6 days ago 89% | 9 days ago 85% | 10 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 78% | 2 days ago 83% |
| Aroon ODDS (%) | 2 days ago 79% | N/A | 2 days ago 87% |
Advertisement
SRRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SRRK has been loosely correlated with ORMP. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if SRRK jumps, then ORMP could also see price increases.
| Ticker / NAME | Correlation To SRRK | 1D Price Change % | ||
|---|---|---|---|---|
| SRRK | 100% | -2.73% | ||
| ORMP - SRRK | 42% Loosely correlated | -1.89% | ||
| PLRX - SRRK | 41% Loosely correlated | -1.59% | ||
| VTGN - SRRK | 40% Loosely correlated | +12.01% | ||
| SNDX - SRRK | 39% Loosely correlated | +6.86% | ||
| ERAS - SRRK | 38% Loosely correlated | +4.46% | ||
More | ||||